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Phagocytosis of apoptotic cells by myeloid cells has
been implicated in the maintenance of immune
homeostasis. In this study, we found that T cell
immunoglobulin- and mucin domain-containing
molecule-4 (TIM-4) repressed tumor-specific immu-
nity triggered by chemotherapy-induced tumor cell
death. TIM-4was found to be highly expressed on tu-
mor-associated myeloid cells such as macrophages
(TAMs) and dendritic cells (TADCs) and danger-asso-
ciated molecular patterns (DAMPs) released from
chemotherapy-damaged tumor cells induced TIM-4
on tumor-associated myeloid cells recruited from
bone marrow-derived precursors. TIM-4 directly
interacted with AMPKa1 and activated autophagy-
mediated degradation of ingested tumors, leading
to reduced antigen presentation and impaired CTL
responses. Consistently, blockade of the TIM-4-
AMPKa1-autophagy pathway augmented the anti-
tumor effect of chemotherapeutics by enhancing
tumor-specific CTL responses. Our finding provides
insight into the immune tolerance mediated by
phagocytosis of dying cells, and targeting of the
TIM-4-AMPKa1 interaction constitutes a unique
strategy for augmenting antitumor immunity and
improving cancer chemotherapy.
INTRODUCTION
Tumormicroenvironments play adeterminant role in suppressing
responsiveness to anticancer drugs and accelerating subse-
quent tumor growth (Hanahan and Coussens, 2012). Therefore,
it is extremely difficult to treat established tumors in which the
complex interplay between tumor cells and stromal components1070 Immunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Inis already skewed in favor of tumor progression. Recent evi-
dences have clarified the critical role of intrinsic host immunity
in the regulation of tumor sensitivities to anticancer drugs. In
addition, the interactions between antigen-presenting cells
(APCs) and T cells, which are regulated by various repertories
of costimulatory and coinhibitory molecules in tumor microenvi-
ronments, might impact tumor progression and anticancer drug
resistance (Peggs et al., 2007). Consistent with this notion, anti-
body blockade of the major coinhibitory molecules cytotoxic T
lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)
enhances antitumor responses in patients who have been refrac-
tory to other anticancer modalities (Pardoll, 2012). Thus, the mo-
lecular events governing host immunoregulatory elements might
modulate responsiveness toconventional anticancer treatments.
T cell immunoglobulin and mucin domain protein-4 (TIM-4),
which is expressed on myeloid cells including dendritic cells
(DCs) andmacrophages from spleen, lymph nodes, or peritoneal
cavity, serves as a critical sensor for controlling the functions of
naive and activated T cells. TIM-4 differentially regulates T cell
homeostasis by inhibiting naive T cells during the induction
phase of an immune response and enhancing T cell responses
at the effector phase (Rodriguez-Manzanet et al., 2010). In addi-
tion, TIM-4 plays a critical role in phagocytosis of apoptotic cells
by APCs through interaction with phosphatidylserine (PS) (Miya-
nishi et al., 2007; Kobayashi et al., 2007). Although these studies
verify the role of TIM-4 in the regulation of immune homeostasis
by controlling APC functions, it remains unknown how TIM-4
impacts host immunity within tumor microenvironments. In
particular, it is critical to evaluate the role of TIM-4 expressed
on myeloid cells of distinct tissues including tumors in regulating
immunity and tolerance.
In this study, we identified a new pathway whereby TIM-4-
adenosine monophosphate activating kinase-a1 (AMPKa1)
interaction in myeloid cells triggers antigen-specific immune
tolerance by inducing autophagy-mediated degradation of
chemotherapy-killed apoptotic tumor cells. Thus, targeting
TIM-4-AMPKa1 interplay might constitute a novel strategy for
potentiating the antitumor responses.c.
Figure 1. Tumor-Derived DAMPs Upregulate TIM-4 on Myeloid Cells
(A) Expression of TIM-4 on F4/80+ macrophages from tumors, TDL, or SPL of B16-F10 tumor-bearing mice.
(B) TIM-4 on BMDMs treated with the tumor supernatants (TS) of CDDP-treated B16-F10 cells.
(C) TIM-4 on BMDMs cultured with CDDP-treated TS pretreated with blocking Ab for aHMGB1, 17-AAG, Apyrase or all.
(D) GFP+ proportions in F4/80+ TAMs, S-MAC, or P-MAC in lethally irradiated WT C57BL/6 mice transplanted with bone marrow cells from GFP-transgenic mice.
(E) TIM-4 on macrophages in PBL of HD (n = 6) or cancer patients (PT) (n = 3), TAM or TADCs from the same patients (n = 13). Data are shown as mean ± SD
(n = 3–5). See also Figure S1.
Immunity
Immune Regulation by TIM-4-AMPK InteractionRESULTS
DAMPs Released from Chemotherapy-Treated Tumor
Cells Upregulate TIM-4 on Tumor-Associated
Macrophages and Dendritic Cells
We first evaluated TIM-4 expression on myeloid cells from mice
bearing established tumors. Single-cell suspensions prepared
from subcutaneous B16-F10 tumors revealed high percentages
of TIM-4-expressing CD11b+F4/80+ macrophages and CD11c+
MHC-IIhi dendritic cells (DCs) (Figure 1A; Figure S1B). In
contrast, lower percentages of TIM-4+ macrophages were found
in the tumor-draining lymph nodes (TDL) and spleens (SPL) of
tumor-bearing mice (Figure 1A). TIM-4 was not detectable on
lymphocytes (T, B, and NK cells), EpCAM+ epithelial cells,
CD31+ endothelial cells, or CD45 gp38+ stromal cells in tumor
tissues and spleens of tumor-bearing mice, suggesting that
TIM-4 expression was confined to myeloid lineage cells (Fig-
ure S1A; not shown).
To investigate tumor-derived factors contributing to TIM-4 in-
duction in myeloid cells, we incubated immature bone-marrow-Immderived macrophages (BMDMs) or dendritic cells (BMDCs) with
untreated or cisplatin (CDDP)-treated B16-F10 tumor cell super-
natants. TIM-4 expression was upregulated 12 hr after treatment
with the supernatants of CDDP-treated tumor cells at greater
levels than those of untreated cells (Figure 1B). Moreover, TIM-
4 was also induced by the supernatants of MC38 colon cancer
cells treated with CDDP, camptothecin (CPT-11), or gemcitabine
(GEM), as well as 3LL lung cancer cells treated with CDDP, taxol,
or GEM, compared to the cells treated with DMSO (Figure S1C),
suggesting that soluble factors released from chemotherapy-
treated, dying tumor cells contribute to the TIM-4 upregulation
on tumor-associated myeloid cells. Dying tumor cells release
endogenous ligands for pattern recognition receptors referred
as damage-associated molecular patterns (DAMPs) (Krysko
et al., 2012). Although treatment of the dying tumor cell superna-
tant with an inhibitor for high mobility group box-1 (HMGB1)
(anti-HMGB1 Ab), heat shock protein 90 (HSP90) (17-AAG), or
ATP (apyrase) singly had only marginal inhibitory effects on
TIM-4 expression on BMDMs, a combination of all three inhibi-
tors largely diminished the upregulation of TIM-4 on BMDMsunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Inc. 1071
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dium urate (MSU), and S100A8 together caused TIM-4 upregu-
lation on BMDMs or BMDCs (Figure S1D and S1E). Thus, an
inflammatory tumor microenvironment triggered by cytotoxic
chemotherapy induces the TIM-4 upregulation on tumor-associ-
ated macrophages and DCs through the release of DAMPs.
To determine the origin of TIM-4+ TAMs, we examined TAMs
from various tumors established in C57BL/6 mice transplanted
with bone marrow cells (BMCs) from GFP-transgenic mice (Fig-
ure 1D). As previously reported (Geissmann et al., 2010), perito-
neal macrophages were largely radioresistant and contained
about 20% of BMC-derived GFP+ cells, and the GFP+F4/80+
cells were detected in spleens at higher frequency than
peritoneal cavity. In contrast, the majority of TAMs were bone-
marrow-derived GFP+ cells (Figure 1D). Although previous
reports revealed that splenic inflammatory CCR2hi monocytes
might serve as a main reservoir of TAMs (Qian et al., 2011; Cor-
tez-Retamozo et al., 2012), these results suggest that majority of
TAMs might be originated from BMCs.
Finally, we found that TIM-4 expression was also detected on
higher percentages of TAM or TADCs isolated from tumor tis-
sues of patients with advanced non-small-cell lung or gastric
carcinoma than on the same populations obtained from
peripheral blood leukocytes (PBL) of cancer patients or healthy
volunteers (HV) (Figure 1E). These results demonstrate that
tumor-derived DAMPs are responsible for upregulating TIM-4
on myeloid cells.
TIM-4 Differently Regulates Antigen Presentation in
Distinct Macrophage Subsets
Several lines of evidence have revealed the impact of apoptotic
cell engulfment onmaintaining immune tolerance and preventing
excess inflammation (Nagata et al., 2010; Griffith and Ferguson,
2011). Although TIM-4 serves as a PS receptor that facilitates
phagocytosis of apoptotic cells by peritoneal macrophages
(P-MAC), the role of TIM-4 in regulation of phagocytosis by
tumor-infiltrating myeloid cells remains unknown.
To address this issue, we prepared for B16-F10 TAMs or bulk
P-MAC of C57/Bl6 wild-type (WT) mice, which highly expressed
TIM-4 (data not shown), as well as those of TIM-4-deficient mice.
In addition, we isolated TIM-4+ and TIM-4 populations of
BMDMs or splenic macrophages (S-MAC) from WT C57BL/6
mice or those from TIM-4-deficient (Timd4/) mice. We
confirmed that TIM-4 expression was not detected in TIM-4
WT cells even after ingestion of dying tumor cells in our experi-
mental conditions (data not shown). In TIM-4+ WT TAMs,
BMDMs, or splenic macrophages, we found that TIM-4 was
dispensable for phagocytosis of dying EG7 tumor cells, because
the phagocytosis by these cells was not different in TAMs or
BMDMs of TIM-4+ or TIM-4 WT and Timd4/mice, and re-
mained unaffected by treatment with anti-TIM-4 mAb (Figures
2A and 2B; Figures S2A–S2C). In contrast, phagocytosis of
apoptotic EG7 cells was significantly inhibited in Timd4/ and
WT peritoneal macrophages treated with the TIM-4 mAb or a
TIM-4-specific siRNA that suppressed TIM-4 expression (siRNA
#2) (Figures S1D, S2B–S2E). The blocking activities for TIM-4
were intact even when Fab fragments were used, and they
were not affected by Fc receptor blocking with anti-CD32/
CD16 mAb (data not shown). These results suggest differential1072 Immunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Incontribution of TIM-4 to phagocytosis of apoptotic cells by
distinct subsets of macrophages, which might be determined
by expression of other phagocytic receptors.
We next analyzed how TIM-4 regulates antigen presentation
by TAMs and TADCs. TAMs and TADCs were isolated from
B16-OVA-bearing WT or Timd4/ mice treated with or without
CDDP and then used for antigen presentation (SIINFEKL-H2Kb
expression). We found that both TAMs and TADCs from
Timd4/ mice had a superior ability to form SIINFEKL-H2Kb
complex from OVA-expressing B16 tumors pretreated with
CDDP compared to those from WT counterparts (Figure 2C).
Moreover, TIM-4+ BMDMs treated with anti-TIM-4 mAb
augmented cross-priming of OVA-specific T cells at similar
levels to Timd4/ BMDMs (Figures S2A and S2C). Interestingly,
while treatment with anti-TIM-4 mAb or siRNA augmented
SIINFEKL-H2Kb presentation by TIM-4+ TAMs (Figures S2B
andS2E), BMDMs, or splenicmacrophages (Figure S2H), the an-
tigen presentation was substantially impaired in Timd4/ TAMs
or WT TAMs treated with anti-TIM-4 mAb, likely due to the
impaired phagocytosis (Figure 2C; Figures S2C and S2E).
To examine whether TIM-4 regulates APC-mediated cross-
priming of tumor antigen-specific CD8+ cytotoxic T lymphocytes
(CTLs), TAMs and TADCs were isolated from B16-OVA-bearing
WT or Timd4/ mice treated with or without CDDP and then
used for cross-priming of OVA-specific OT-I cells. TIM-4 defi-
ciency augmented interferon-g (IFN-g) production in TCR-Vb5+
OT-I cells when stimulated by TAMs and TADCs isolated from
CDDP-treated B16-OVA tumors, although cross-priming
ability of TADCswere superior to that of TAMs (Figure 2D). More-
over, OVA-specific responses to TIM-4+ BMDMs were also
augmented by anti-TIM-4mAbwhenB16-OVA cells were loaded
after treatment other cytotoxic agents such as CPT-11, taxol, or
GEM (Figure S2F).
The blockade of TIM-4 augmented antigen cross-presentation
while ingestion of dying tumor cells by TAMs remained
intact, suggesting that some other phagocytic receptors might
compensate and stimulate antigen processing by TAMs.
Because recent studies demonstrated the importance of
CD91-calreticulin (CRT) interaction in stimulating phagocytosis
and cross-presentation of immunogenic antigens by APCs
(Obeid et al., 2007), we examined whether CD91 was utilized
as an alternative receptor for phagocytosis by TAMs treated
with anti-TIM-4 mAb. Although CD91 was expressed on TAMs
at comparable levels to P-MAC, treatment with anti-CD91
neutralizing Ab and anti-TIM-4 mAb significantly suppressed
the ingestion of dying EG7 cells and antigen-presentation by
TAMs (Figure S2G). Thus, multiple phagocytic receptors allow
TAMs to utilize TIM-4-independent compensatory pathways.
In process of analyzing the fate of engulfed tumor cells in
TAMs, we found that the ingested apoptotic tumor cells were
located into LAMP1+ lysosomal compartment in TIM-4+ BMDMs
at much higher frequencies than those in Timd4/ BMDMs
(Figure 2E). This finding led us to hypothesize that TIM-4 might
promote lysosomal degradation of the ingested tumor cells,
leading to the impaired tumor antigen presentation by TIM-4+
TAMs. Consistent with this notion, a lysosomal acidification
inhibitor bafilomycin A1 increased the ability of TIM-4+ BMDMs
to stimulate OT-I cells to a comparable level with that of
TIM-4 BMDMs (Figure S3A).c.
Figure 2. TIM-4 Suppresses APC Activities by Dying Tumor Cells
(A) Ingestion of TIM-4+ WT or Timd4/ BMDMs loaded with CDDP-treated PKH26+EG7 cells.
(B) Ingestion of TAMs and P-MAC from WT or TIM-4/ mice with CDDP-treated EG7 cells.
(C) OVA antigen presentation of TAMs, TADCs, or P-MAC isolated from tumors of Timd4/mice inoculated with OVA-B16 cells. TheMFI of SIINFEKL-H2Kb+ was
quantified by flow cytometry.
(D) Percentage of IFN-g+ cells in OT-1 cells cocultured with TADCs or TAMs.
(E) Lysosomal degradation of TIM-4+ WT or Timd4/ BMDMs loaded with CDDP-treated CFSE+ EL4 cells. Data are shown as mean ± SD (n = 3–5). See also
Figure S2.
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immune tolerance by promoting phagosomal acidification and
antigen overdegradation in macrophages localized in tumors,
bone marrow, or spleen.
TIM-4 Suppresses Antigen Presentation by Autophagy-
Mediated Mechanisms
We next examined which signaling cascades are involved in the
impaired antigen presentation by TIM-4+ BMDMs. Since treat-
ment with an mammalian target of rapamycin (mTOR) inhibitor
rapamycin, a phosphoinositide 3-kinase (PI3K) class-IA p110-
d-specific inhibitor IC87114 or the genetic deficiency of p85a
repressed OT-I cell activation by TIM-4 BMDMs to comparable
levels with TIM-4+ counterparts. In contrast, the treatment
with a PI3K class III-specific inhibitor 3-methyladenine (3-MA)
augmented the activation by TIM-4+ BMDMs to the levels com-
parable with TIM-4 counterparts (Figures S3A and S3B).
These findings led us to hypothesize e involvement of
autophagy on TIM-4-mediated immune regulation, becauseImmautophagy serves as a main pathway regulated by multiple
signaling cascades such as PI3K and mTOR (Levine et al.,
2011). Moreover, autophagy is critically involved in multiple pro-
cesses of immune regulation, such as MHC class II-mediated
antigen presentation and regulation of cytokine profiles re-
sponses (Lee et al., 2010; Saitoh et al., 2008). Furthermore, the
TIM-4-mediated uptake of apoptotic cells facilitated microtu-
bule-associated protein light chain 3 (LC3)-associated phago-
some formation (Martinez et al., 2011). Thus, we examined
whether TIM-4 might promote degradation of ingested cells by
activating autophagic pathways.Consistent with this idea, inges-
tion of dyingEL4cells resulted in enhancedautophagic activation
of TIM-4+ BMDMs generated from LC3-GFP transgenic mice
(Mizushima et al., 2004), as shown by the increased frequencies
of punctuate form of LC3 (Figure 3A). In addition, phagocytosis
of dying EG7 cells decreased intensity of LC3 levels in TIM-4+
WT BMDMs, which suggest increased autophagy-mediated
degradation, whereas LC3 expression remained unchanged
in Timd4/ BMDMs after engulfment of dying EG7 cellsunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Inc. 1073
Figure 3. TIM-4 Regulates Cross-Presentation by Activating Autophagic Pathways
(A) Distribution of LC3 in TIM-4+, TIM-4 BMDMs, or P-MAC from LC3-GFP-TG mice loaded with CDDP-treated EG7 cells or received amino-acid starvation
(EBSS).
(B and C) LC3-I/II levels in TIM-4+ or Timd4/ BMDMs loaded with CDDP-treated EG7 cells or received EBSS with or without CLQ.
(C) Distribution of LC3 in TIM-4+ or Timd4/ BMDMs treated as shown in (B).
(D) Formation of autophagosome in TIM-4+ or Timd4/ BMDMs as shown in (B). The autophagic vesicles (arrow head) containing dying cell debris (*) were
shown. Scale bar represents 4 mm (upper panel) and 1 mm (lower panel).
(E) IFN-g production in OT-I cells cocultured with BMDMs from WT or LysM-Atg5/ mice loaded with CDDP-treated EL4 or EG7 cells and control Ig or aTIM-4.
(F) Phagocytosis, autophagy, and lysosomal degradation of TIM-4+ WT or Timd4/ BMDMs loaded with CDDP-treated PKH26+EL4 cells for the indicated time.
The MFI of PKH26, LAMP1, or LC3B levels in the F4/80+ cells were evaluated by flow cytometry. The phagocytosed and autophagy-activated cells were
calculated as increased percentages of PKH26+ EL4 cells and reduced percentages of LC3-positive cells loaded with dying EL4 cells compared to untreated
cells, respectively.
(G) Efficiency of ULK1 inhibition in BMDMs transfected with ULK1 siRNA.
(H and I) LC3B levels (H) or the presentation of SIIINFEKL-H2Kb (I) in ULK1 siRNA-transfected TIM-4+ or TIM-4 BMDMs loaded with CDDP-treated B16 or
B16-OVA cells. The MFI of SIIINFEKL-H2Kb+ cells are shown. Data are shown as mean ± SD (n = 3–5). See also Figure S3.
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shown by enhanced LC3-II with lysosomal inhibitor chloroquine
(CLQ), further confirming the role of TIM-4 in stimulating autopha-
gic response, whereas autophagic flux was not observed in
TIM-4/ BMDMs upon ingestion of apoptotic cells (Figures 3B
and 3C). Electron microscopic analysis further revealed that the
formation of autophagosomewith double-layermembranes con-
taining degrading cell debris and organelles was detected in
TIM-4+ BMDMs, but autophagic vesicles were barely detectable
in Timd4/- BMDMs, upon engulfment of dying cells (Figure 3D).
To further gain insights into the importance of autophagic ma-
chinery in the TIM-4- mediated regulation, we generated LysM-
Cre 3 Atg5flox/flox conditional gene-targeted (LysM-Atg5/)1074 Immunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Inmice, which are specifically defective of autophagy in myeloid
lineage cells. We confirmed that Atg5 was specifically deleted
and autophagic activities were impaired in the LysM-Atg5/
BMDMs (data not shown). F4/80+CD11b+ macrophages were
generated from bone marrow cells of WT or LysM-Atg5/
mice, loadedwith dying EL4 or EG7 cells for 4 hr, and then cocul-
tured with OVA-specific OT-I cells. LysM-Atg5/ BMDMs had
a greater potential in stimulating OT-I cells as compared to WT
BMDMs, and the levels of antigen presentation by LysM-
Atg5/ BMDMs were comparable to those by TIM-4/
BMDMs (Figure 3E). In accord with the significance of crosstalk
between TIM-4 and autophagic pathways, treatment with anti-
TIM-4 mAb or siRNA-mediated inhibition of TIM-4 had littlec.
Immunity
Immune Regulation by TIM-4-AMPK Interactionadditional effects on the antigen presentation or the cross-prim-
ing of OT-I cells by TIM-4+LysM-Atg5/ BMDMs (Figure 3E;
Figure S3D). Furthermore, whereas the anti-TIM-4 mAb-medi-
ated enhancement of cross-priming by WT BMDMs was abol-
ished by rapamycin and IC87114, the enhanced cross-priming
by LysM-Atg5/ BMDMs was not affected by these inhibitors
(Figure S3E).
The LAMP1+ phagolysosome containing dying cells was
detected in TIM-4+ BMDMs at similar levels to Timd4/BMDMs
up to 30 min after phagocytosis of dying EL4 cells. However, the
LAMP1 levels increased continuously in TIM-4+ BMDMs, while it
gradually decreased in Timd4/ BMDMs after 30 min, whereas
the kinetics of phagocytosis were similar in TIM-4+ WT and
Timd4/BMDMs (Figure 3F). Furthermore, autophagywas acti-
vated in TIM-4+ BMDMs but not Timd4/ BMDMs after inges-
tion of dying EL4 cells, suggesting that autophagy activation
occurred selectively in TIM-4+ cells (Figure 3F). These results
suggested that TIM-4 was dispensable for phagolysosome
formation following apoptotic cell phagocytosis, but it played a
critical role in initiating autolysosome formation, leading to
excessive antigen degradation and reduced cross-presentation
by TIM-4+ macrophages.
Recent studies have revealed that engulfment of TLR-associ-
ated particles or recognition of PSmediates a recruitment of LC3
to mature phagosomes through class III PI3K and Atg5-depen-
dent but Unc51-like linase-1 (ULK1)-independent machineries
(Sanjuan et al., 2007; Martinez et al., 2011). This process,
referred as LC3-associated phagocytosis (LAP), does not cause
an accumulation of autophagic vesicles and is responsible for
facilitating dying cell clearance and TLR-mediated innate
immune responses (Martinez et al., 2011; Henault et al., 2012).
However, we observed the clear autophagic vesicles, which
were colocalized with luminal ER tracker in TIM-4+ BMDMs
upon tumor cell phagocytosis (Figure 3A; data not shown). More-
over, siRNA-mediated targeting of ULK1, which efficiently
inhibits ULK1 expression (Figure 3G), reversed the TIM-4-medi-
ated activation of autophagy and the repressed cross-presenta-
tion in TIM-4+ BMDMs upon ingestion of EL4 cells (Figures 3H
and 3I). Thus, our findings strongly suggest that TIM-4 in-
duces tolerogenic properties of myeloid cells upon recognition
of apoptotic cells in conventional autophagy-dependent but
LAP-independent manner. Then, we further investigated how
TIM-4 regulates conventional autophagy after engulfment of
dying tumor cells.
TIM-4 Interacts with AMPKa1 in Phagosome and
Activates Autophagic Processes
Autophagy is tightly regulated by multiple molecules and path-
ways sensing stresses in the cells (Levine et al., 2011). Interest-
ingly, TIM-4 was expressed mostly on the cell surface, but it was
localized at LAMP1+ phagolysosome after ingestion of apoptotic
EL4 cells (Figure S4A), suggesting that TIM-4 might act on phag-
osome to regulate autophagy. We next tried to identify the mole-
cule that directly interacts with TIM-4 and regulates autophagy.
Although the autophagic activity is controlled by mTORC1
pathway regulators, such as SH3BP1, REDD, GSK-b, and
FoxO (Levine et al., 2011), we failed to detect the involvement
of these factors in the TIM-4-mediated regulation of autophagy
(data not shown).ImmRecent studies have revealed that AMPKa interacts with ULK1
and activates autophagy (Egan et al., 2011; Kim et al., 2011).
Furthermore, AMPKa was detected in macrophages upon the
phagocytosis of apoptotic cells (Bae et al., 2011), which stimu-
lated autophagy by inhibiting tuberous sclerosis protein-2
(TSC2)-mTORC1 (mTOR complex 1) signals (Hardie, 2007).
Thus, we investigated whether AMPKa was involved in the
TIM-4-mediated regulation of autophagy. We found that TIM-4
interacted with AMPKa1 in TIM-4+ BMDMs after ingestion of
dying EL4 cells, although TIM-4 binding with AMPKa1 was
detected at lower levels even without phagocytic process (Fig-
ure 4A). We next examined the impact of TIM-4 on the activation
of AMPK and autophagy. Phosphorylation of AMPKa1 at Thr172,
which is critical for its kinase activities, was clearly induced in
TIM-4+ BMDMs, but not in Timd4/ BMDMs or P-MACs,
upon ingestion of dying EL4 cells (Figure 4B). More interestingly,
TIM-4 was colocalized with AMPKa1 in LAMP1+ and LC3+ auto-
phagolysosomal vesicles after phagocytosis of apoptotic cells
(Figures 4C and 4D).
We next examined the role of the TIM-4-AMPKa interaction in
the regulation of mTOR signals and autophagic activities. The in-
hibition of AMPKa in TIM-4+ BMDMs augmentedmTORC1 activ-
ities as shown by the increased phosphorylation of p70 and p85
S6K1 (Figure S4B). Moreover, TIM-4-AMPKa interaction pro-
moted phosphorylation of ULK1 at Ser555, which is critical to
recruit Atg13/FIP200 and initiate autophagic vesicle formation
(Egan et al., 2011) (Figure 4E). TIM-4 and AMPKa1 were colocal-
ized with ULK1 in LAMP1+ lysosomal vesicles (Figure 4F). The
importance of TIM-4-AMPKa1 interaction in the regulation of
autophagy was further validated by analyzing AMPKa1-deficient
(Prkaa1/) TIM-4+ BMDMs, because LC3-II expression was
impaired in Prkaa1/ BMDMs upon ingestion of EL4 cells (Fig-
ure 4G; Figure S5A). In contrast, AMPKa2 deficient (Prkaa2/)
TIM-4+ BMDMs activated autophagy upon ingestion of dying
EL4 cells at similar levels to WT counterparts, indicating that
a1-subset of AMPK specifically interacts with TIM-4. These
results are consistent with previous reports that AMPKa1 is a
sole subset specifically expressed in myeloid cells (Sag et al.,
2008; Yang et al., 2010). Moreover, BMDCs activated autophagy
upon ingestion of dying tumor cells by TIM-4-dependent
mechanisms, suggesting that TIM-4-mediated activation of
autophagy is commonly operated in macrophages and DCs
(data not shown).
The above finding led us to hypothesize that different dyna-
mism and/or activities of AMPKa1 might be a determinant
in regulating the APC activities of TIM-4+ macrophages. The
phosphorylation levels of AMPKa1 were comparable among
TAMs, BMDMs, and peritoneal macrophages upon ingestion of
apoptotic cells (data not shown). However, TIM-4 was colocal-
ized with AMPKa1 in the intracellular compartments of TAMs
and TIM-4+ BMDMs upon ingestion of apoptotic cells, whereas
TIM-4 was mostly retained on plasma membrane and thus
scarcely interacted with AMPKa1 in peritoneal macrophages
(Figure 4H). These results suggest the existence of molecular
machineries regulating TIM-4 internalization after recognition of
apoptotic cells, which differed among macrophage subsets.
Collectively, TIM-4 activates AMPKa1 in TAMs and BMDMs
upon ingestion of apoptotic cells, leading to the ULK1-mediated
formation of autophagic vesicles.unity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Inc. 1075
Figure 4. TIM-4-AMPKa1 Interaction Is Critical for Activating Autophagy
(A) CoIP of TIM-4 with endogenous AMPK-a in TIM-4+ BMDMs loaded with CDDP-treated EL4 cells.
(B) Phosphorylated and total levels of AMPKa1 in TIM-4+, Timd4/ BMDMs, or P-MAC loaded with CDDP-treated EL4 cells. The ratio of p-AMPKa1/total
AMPKa1 densitometry was shown.
(C and D) Localizations of TIM-4, AMPKa1, and LAMP1+ (C) or LC3 (D) in TIM-4+ BMDMs cultured with or without CDDP-treated EL4 cells. (E) Phosphorylation of
ULK1 in TIM-4+ or TIM-4 WT BMDMs were treated as described in (B).
(F) Localizations of LAMP1, TIM-4, AMPKa1, and ULK1 in TIM-4+ BMDMs loaded with dying EL4 cells.
(G) LC3-II levels in TIM-4+ or Timd4/ BMDMs from WT or Prkaa1/ mice loaded with CDDP-treated EL4 cells (EL4 [+]) or not (EL4 [–]).
(H) Localizations of TIM-4 and AMPKa1 in TAMs, TIM-4+ BMDMs, and P-MAC cultured with or without CDDP-treated EL4 cells. See also Figure S4.
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Antitumor Effect of Chemotherapy
To examine the involvement of TIM-4-autophagy pathway, we
characterized the antitumor effects of CDDP and anti-TIM-4
mAb on MC38 colon cancer growth in the LysM-Atg5/ or con-
trol Atg5flox/flox mice. The combined treatment with CDDP and
anti-TIM-4 mAb resulted in a significant delay of tumor growth
in the Atg5flox/flox mice (Figure 5A). In contrast, CDDP mono-
therapy was sufficient to suppress tumor growth in the LysM-
Atg5/ mice at a similar extent to combined treatment with
CDDP and anti-TIM-4 mAb (Figure 5A). To analyze the mecha-
nisms underlying these effects, we adoptively transferred OT-I
cells into LysM-Atg5/ or control Atg5flox/flox mice. Two days
later, B16-OVA cells were inoculated subcutaneously and the
mice were then treated with CDDP and/or anti-TIM-4 mAb. Lym-
phocytes were isolated from the established tumors 7 days after
the final treatment. The CDDP alone was sufficient to maximize
the frequencies of TCR-Vb5+ OT-I cells and IFN-g-producing
OT-I cells in the LysM-Atg5/ mice, whereas the combination
with anti-TIM-4 mAb was required for maximizing antitumor
effects in the control Atg5flox/flox mice (Figures 5B and 5C).
Recent studies demonstrated that some chemotherapeutic
agents trigger immunogenic cell death (ICD) of tumors, which1076 Immunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Inwas associated with tumor immunogenicity and antitumor re-
sponses (Green et al., 2009). Because a cytotoxic drug that
has been known as a non-ICD inducer (CDDP) was utilized in
this study, we next examined how TIM-4-autophagy pathway
regulates antitumor responses of ICD inducers (oxaliplatin
[OXP], doxorubicin, and g-irradiation) as compared to non-ICD
inducers (CDDP, CPT-11, and mitomycin-C) (Green et al.,
2009). Cross-priming of OT-I cells by EG7-loaded BMDMs was
significantly augmented irrespective of the frequencies with
either ICD or non-ICD inducers (Figure S5B). Although OXP
monotherapy substantially suppressed tumor growth in the
LysM-Atg5/ mice, the treatment with anti-TIM-4 mAb further
augmented antitumor effect of OXP in the Atg5flox/flox mice (Fig-
ure S5C). Thus, TIM-4-autophagy pathways regulate antitumor
responses of chemotherapeutic agents that trigger either ICD
or not.
To further define the role of TIM-4 on myeloid cells in regu-
lating antitumor effect of chemotherapy-induced adaptive im-
munity, we generated mixed BM chimeric mice comprising
BMCs from WT or Timd4/ and LysM-Atg5/ mice. In this
setting, BMCs from Atg5flox/flox, LysM-Atg5/, and Timd4/
or WT mixed with LysM-Atg5/ mice at a 1:1 ratio were used
to reconstitute lethally irradiated WT recipient mice. Twoc.
Figure 5. TIM-4-Autophagy Pathway Attenuates Antitumor Effects of Chemotherapy
(A) MC38 tumor growth in LysM-Atg5/ or Atg5flox/flox mice treated with CDDP and control Ig or aTIM-4 (n = 4 per group).
(B and C) Total number of CD8+ TCR-Vb5+ OT-I cells (B) or IFN-g+ populations of OT-I cells (C) in tumor-infiltrating lymphocytes.
(D) B16-OVA tumor growth in mice reconstituted with BM cells of Atg5flox/flox, LysM-Cre-Atg5/, Timd4/, and LysM-Atg5/ (Timd4/--LysM-Atg5/) or WT
and LysM-Atg5/ (WT/LysM-Atg5/ chimera) mice 3 days after intravenous transfer of OVA-specific TCR-Vb5+ cells and treated with CDDP. Schematic
representation of experimental approach is shown (left panel). Data are shown as mean ± SD (n = 3–5). See also Figure S5.
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with B16-OVA tumor cells into the each BM chimeras and
treated with CDDP or OXP to induce antigen-specific immune
responses in vivo. The antitumor effects of CDDP were
compared in Atg5flox/flox, LysM-Atg5/, Timd4/ -LysM-
Atg5/, or WT-LysM-Atg5/ chimeras. CDDP or OXP had a
superior antitumor effect on B16-OVA tumors in LysM-Atg5/
BM chimeras compared to Atg5flox/flox counterparts. Impor-
tantly, the antitumor effect of CDDP or OXP was severely
impaired in WT-LysM-Atg5/ BM chimeras compared to
LysM-Atg5/ BM mice, whereas both chemotherapies had a
potent antitumor effect in Timd4/-LysM-Atg5/BM chimeras
at comparable levels to LysM-Atg5/ BM chimeras (Figure 5D;
Figure S5C).
Together, these findings further substantiate the role of TIM-
4-autophagy pathway in negatively regulating chemotherapy-
induced antitumor immunity.ImmThe TIM-4-AMPKa1-Autophagy Pathway Attenuates
Antitumor Effects of Chemotherapy
We next evaluated whether the TIM-4-AMPKa1 interaction is
responsible for the attenuation of chemotherapeutic effects by
TIM-4-mediated activation of autophagy. To do so, TIM-4+
BMDMs were loaded with apoptotic EG7 cells in the presence
of AMPK inhibitor (compound C) or activator (5-Aminoimida-
zole-4-carboxyamide ribonucleoside: AICAR) or transfected
with siRNA specifically targeting for AMPKa1 and AMPKa2.
The cells were then used to stimulate OT-I cells. TCR-Vb5+
OT-I cells produced more IFN-g when stimulated by TIM-4+
BMDMs treated with the AMPK inhibitor or transfected with
AMPKa-specific siRNA. Moreover, TIM-4 blockade had little
impact on the stimulation by TIM-4+ BMDMs when AMPK was
inhibited (Figure 6A). In contrast, the TIM-4 blockade could not
overcome the immunosuppressive properties of TIM-4+ BMDMs
or decreased the immunogenic potential of TIM-4-deficientunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Inc. 1077
Figure 6. The TIM-4-AMPKa1 Pathway Attenuates Antitumor Effect of Chemotherapy and Tumor-Specific Immune Responses
(A) IFN-g production of OT-1 cells stimulated by the AMPKa siRNA-transfected TIM-4+ or TIM-4 BMDMs loaded with CDDP-treated EG7 cells.
(B) OVA presentation of TIM-4+ or TIM-4 BMDMs from WT, Prkaa1/, or Prkaa2/ mice loaded with CDDP-treated EG7 cells and control Ig or aTIM-4.
(C) IFN-g production in TCR-Vb5+ OT-I cells cocultured with TIM-4+ or TIM-4 WT or Prkaa1/ BMDMs loaded with CDDP-treated EG7 cells.
(D) Subcutaneous MC38 tumor growth in the BM chimeras reconstituted with LysM- Prkaa1/ or Prkaa1flox/flox BM cells and treated with CDDP and aTIM-4. For
some instances, anti-CD8 depleting Ab was administered 2 days prior to tumor inoculation. (n = 4 per group).
(E) B16-OVA tumor growth in the mice reconstituted with BM cells from Prkaa1flox/flox, LysM-Prkaa1/, Timd4/, and LysM-Prkaa1/ mice (TIM-4/-LysM-
Prkaa1/ chimera) or WT and LysM-Prkaa1/ mice (WT-LysM-Prkaa1/ chimera) 3 days after intravenous transfer of OVA-specific TCR-Vb5+ cells from OT-I
mice, and treatedwith CDDP. The schematic representation of experimental approach is shown (top). Data are shown asmean ± SD (n = 3–5). See also Figure S6.
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Immune Regulation by TIM-4-AMPK InteractionBMDMs when pretreated with the AMPK activator AICAR (Fig-
ure S6A). Furthermore, BMDMs and BMDCs generated from
Prkaa1/ mice exhibited OVA cross-presentation at greater
levels than WT counterparts irrespectively of the treatment with
anti-TIM-4 mAb or TIM-4-specific siRNA. In contrast, OVA-pre-
sentation was similarly compromised in Prkaa2/ and WT
BMDMs in TIM-4-dependent manner, suggesting that a1 subunit
of AMPK is critical to interact with TIM-4 and suppress cross-
priming by apoptotic cell-derived antigens (Figure 6B;
Figure S6B).
Liver kinase B1 (LKB1)-mediated phosphorylation of AMPKa
serves as a critical pathway to activate tuberous sclerosis
complex (TSC) andsuppressesmTOR1 (Alessi et al., 2006). How-
ever, TIM-4 activated autophagy and inhibited OVA antigen-
presentation in LKB1/ macrophages at similar levels to WT
BMDMs, suggesting that AMPKa1 regulates TIM-4-mediated
immune tolerance by LKB1-independent manner (Figure S6C).1078 Immunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier InTo define the role of TIM-4-AMPKa1 pathway in myeloid cells
in the regulation of chemotherapy-induced antitumor immune re-
sponses in vivo, we generated BM chimeric mice in which BMCs
from control Prkaa1flox/flox or LysM-Prkaa1/ mice were recon-
stituted in lethally irradiatedWTmice. Twomonths after the BMT
procedure and confirmation of the chimerism by LysM-Cre gene
detection, MC38 colon carcinoma cells were inoculated subcu-
taneously and then treated with CDDP or OXP in the presence of
aTIM-4 mAb or control Ig. In this system, we showed the impor-
tance of TIM-4-AMPKa1 pathway inmyeloid cells in suppressing
antitumor effect of OXP, because chemotherapy alone had
a remarkable antitumor effect in LysM-Prkaa1/ BM chimeras
compared to those in Prkaa1flox/flox controls, whereas anti-
TIM-4 mAb augmented antitumor effect of CDDP or OXP in
the Prkaa1flox/flox chimeric mice. More importantly, depletion of
CD8+ cells mostly diminished antitumor effects of chemotherapy
in LysM-Prkaa1/ BM chimeras, as well as CDDP or OXPc.
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Immune Regulation by TIM-4-AMPK Interactioncombined with anti-TIM-4 mAb in Prkaa1flox/flox chimeras, vali-
dating the importance of adaptive immunity in this system (Fig-
ure 6D; Figure S6D). The depletion of CD8+ cells had little effect
on tumor growth without the treatment with CDDP in our exper-
iments (Figure 6D).
To further clarify the role of TIM-4 on myeloid cells in the regu-
lation of chemotherapy-induced antitumor immunity in vivo, we
generated mixed BM chimeric mice comprising of bone marrow
(BM) cells from WT or Timd4/- and LysM-Prkaa1/ mice.
BMCs from Prkaa1flox/flox, LysM-Prkaa1/, andTimd4/ or
WT mixed with LysM-Prkaa1/ mice at a 1:1 ratio were used
to reconstitute irradiated WT recipient mice. Two months after
the BMC reconstitution, OT-I cells were adoptively transferred
with B16-OVA tumor cells into the each BM chimera and treated
with CDDP to evaluate antigen-specific immune regulation.
CDDP had a superior antitumor effect in LysM-Prkaa1/ BM
chimeras compared to Prkaa1flox/flox counterparts. Importantly,
the antitumor effect of CDDP was severely impaired in WT-
LysM-Prkaa1/ BM chimeras compared to LysM-Prkaa1/
BM mice, whereas CDDP had a potent antitumor effect in
Timd4/-LysM-Prkaa1/ BM chimeras at comparable levels
to LysM-Prkaa1/ BM chimeras (Figure 6E). Together, these
findings indicate that TIM-4-AMPKa1 interaction in myeloid cells
attenuates therapeutic effect of chemotherapy by repressing
tumor-specific CD8+ T cell immune responses.
DISCUSSION
We have demonstrated in this study that the interaction between
TIM-4 and AMPKa1 links phagocytosis of apoptotic cells with
immune tolerance. TIM-4 was highly expressed on tumor-asso-
ciated myeloid cells, which were predominantly recruited from
bone marrow, and DAMPs released from dying tumor cells
upon cytotoxic chemotherapy-augmented TIM-4 expression
on the myeloid cells. TIM-4 on the surface of myeloid cells was
translocated to LAMP1+ phagosomes after phagocytosis of
apoptotic cells and then interacted with AMPKa1. The TIM-4-
mediated activation of AMPKa1 led to formation of autophagic
vesicles by activating ULK1 and repressingmTOR signals, which
resulted in excess degradation of tumor-cell-derived antigens in
autophagolysosomes and thereby suppressed cross-priming of
tumor-specific CTL. In this regard, our findings that TIM-4-medi-
ated phagocytosis activates the canonical autophagic pathway
might differ from the recently reported LC3-associated phago-
cytosis, because TIM-4 induced canonical autophagy character-
ized by ULK1-dependent autophagic vesicle formation was
observed following phagocytosis of apoptotic cells. Thus, our
findings have revealed the molecular link whereby phagocytosis
regulates immune responses to tumor or self-antigens derived
from apoptotic cells, and targeting TIM-4-AMPKa1 pathway pro-
vide a novel strategy for augmenting immunogenic cell death
upon chemotherapy while attenuating autoimmunity.
We observed that TIM-4 expression was significantly upregu-
lated on macrophages and DCs in the tumor microenvironments
and demonstrated that DAMPs such as HMGB1, HSP90, MSU,
S100A8, and ATP released from damaged tumor cells were
responsible for upregulating TIM-4 expression onmacrophages.
Because TIM-4 mediates phagocytic clearance of apoptotic cell
debris, the TIM-4 induction by DAMPs released from dying cellsImmmight be relevant in physiological conditions. Given the immuno-
suppressive function of TIM-4 on APCs as described in this
study, it will be of great interest to examine the expression of
TIM-4 in various diseases such as chronic infections and autoim-
mune diseases, in which DAMPs are implicated in the pathogen-
esis. DAMP-mediated induction of TIM-4 on macrophages may
not only facilitate the clearance of damaged cells but also
dampen autoimmune responses by suppressing cross-priming
with self-antigens. This notion is consistent with the develop-
ment of autoimmunity in TIM-4-deficient mice (Rodriguez-Man-
zanet et al., 2010).
Autophagy either promotes or suppresses tumor growth
depending on oncogenic and metabolic alterations in different
tumor cells and their microenvironments (Kimmelman, 2011;
White, 2012). In addition, cytotoxic chemotherapy triggers cell
death pathways by activating autophagic machineries, whereas
autophagy protects tumor cells from cell death triggered by
chemotherapy in certain circumstances (White, 2012). Thus, mo-
lecular mechanisms by which autophagic pathways differently
regulate antitumor effects of cytotoxic chemotherapy remain
largely elusive. Our findings of TIM-4-mediated degradation
of tumor antigens by autophagy provide evidence that autopha-
gic pathways might be involved in immunosuppressive property
of chemotherapy under the conditions that TIM-4-expres-
sing myeloid cells are abundantly infiltrated into the tumor
microenvironments.
Accumulating evidences have revealed that the receptor-
mediated uptake of apoptotic cells modulates multiple signaling
cascades, such as those regulating cytoskeletal organization,
energy, and immune homeostasis (Nagata et al., 2010). Although
LC3-associated phagocytosis is frequently observed upon
recognition of apoptotic cells, it remains largely unknown
whether the recognition of apoptotic cells by some phagocytic
receptors directly induce autophagic vesicle formation and
activation of conventional autophagy. Contrary to the role of
autophagy as a critical defense system to prevent microbes
from evading phagosomal degradation (Levine et al., 2011), we
demonstrate that autophagic degradation of ingested tumor
cells might cause a detrimental effect on antitumor immunity
by abolishing immunogenic antigens available for stimulating
tumor-specific CTLs. Thus, temporal and spatial cooperation
of phagocytosis and autophagy-mediated overdegradation of
tumor antigens might constitute a critical determinant for tumor
evasion from immunosurveillance after cytotoxic chemotherapy.
Consistent with this notion, we have demonstrated here that
blockade of the TIM-4-AMPKa1-autophagy pathway signifi-
cantly augmented the antitumor effects of chemotherapy in
CTL-dependent manner.
Although AMPK serves as an energy checkpoint in cellular
metabolism and homeostasis, recent studies unveiled the role
of AMPK in regulation immune functions of various lymphocyte
subsets, including differentiation of memory CD8+ T cells and
tolerance induction by APCs (O’Neill and Hardie, 2013). In this
study, we provided evidence that AMPKa1 mediates immune
tolerance with TIM-4 in LAMPK1+ phagosome upon ingestion
of apoptotic cells, which leads to ULK1 phosphorylation and
autophagy activation.
Although AMPK activator such as antidiabetic drug metformin
plays an essential role in reprogramming metabolic profiles inunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier Inc. 1079
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lignant diseases (Gallagher and LeRoith, 2011; Faubert et al.,
2013). In marked contrast, our findings revealed that TAMs
impede anticancer effects of cytotoxic chemotherapy through
TIM-4-AMPKa1 pathway in myeloid cells. Thus, it is critical to
clarify the optimal conditions in which particular types of anti-
cancer drugs should be combined with AMPK activator to avoid
TIM-4-mediated immune tolerance. In addition, AMPK activator
might have an additional role to control autoimmunity such as
diabetes by suppressing immunogenic antigen presentation
when TIM-4 on myeloid cells recognizes apoptotic cells.
Together, these multifaceted properties of AMPK highlight the
need for a more deep understanding of how AMPK regulates
tumor environments, which will be essential to develop drugs
targeting AMPK-related signals to optimize their therapeutic
potential to inflammatory disorders such as cancer, autoimmu-
nity, and chronic infection.
Different subsets of macrophages are characterized by
phenotypic diversity, anatomical location, and their functions
(Geissmann et al., 2010). We show here the distinct properties
of myeloid cells from peritoneal cavity, bone marrow, and tumor
tissues in the context of TIM-4-mediated regulation of phagocy-
tosis and antigen presentation. These differences relied mainly
upon the differential potential of AMPKa1 activities in each
macrophage subset by specific environmental stress, because
TIM-4 was preferentially interacted with AMPKa1 in TAMs than
peritoneal macrophages after engulfment of dying tumor cells.
These findings revealed that a different threshold of particular
molecular signals in the macrophage subsets might serve as a
determinant factor to control quality and intensity of local im-
mune responses when encountered with potential immunogenic
materials.
In summary, our present study has revealed a mechanism for
the tolerogenic property of apoptotic cells through TIM-4-medi-
ated activation of AMPKa1 in phagocytic APCs, which compro-
mised the immunogenic antitumor effects of chemotherapy.
Thus, targeting of the TIM-4-AMPKa1 pathway would be also
effective to augment antitumor immune responses after general
cytotoxic cancer therapies such as radiation, immunotoxins, and
adaptive transfer of CTLs. In addition, the TIM-4-AMPKa1
pathway might also be involved in the maintenance of peripheral
immune tolerance and the pathogenesis of autoimmune dis-
eases. Further studies are needed to address these possibilities.
EXPERIMENTAL PROCEDURES
TIM-4 Expression on Myeloid Cells
TIM-4 expression on macrophages prepared from tumors or normal tissues of
tumor-bearing mice was analyzed by flow cytometry with a mAb against
mouse TIM-4 (RMT4-53). In tumor tissues obtained from cancer patients,
the TIM-4 levels on macrophages or DCs were also examined by flow cytom-
etry with an anti-human TIM-4 mAb.
In Vitro Cross-Priming Assay
TIM-4+ WT or Timd4/ cells were cocultured with chemotherapy-treated
tumor cells for 4 hr, and then the cells were subjected to antigen presentation
analysis by quantifying OVA peptide (SIINFEKL)-H2Kb complex on the cell sur-
face with 25-D1.16 mAb. For some instances, the cells were pretreated with
various inhibitors or activators (see Supplemental Experimental Procedures)
for 4 hr before loading with the tumor cells. Intracellular IFN-g expression in
TCR-Vb5+ OT-I cells was determined by flow cytometry.1080 Immunity 39, 1070–1081, December 12, 2013 ª2013 Elsevier InIn Vivo Tumor Studies
WT, LysM-Atg5/ Atg5flox/flox, LysM-Prkaa1/, or Prkaa1flox/flox mice were
injected subcutaneously with 1 3 105 live tumor cells. Chemotherapeutics
(see Supplemental Experimental Procedures) were administered i.p. to the
mice on days 8, 10, and 12 in the presence of anti-TIM-4 mAb or isotype-
matched control Ig. Tumor growth was measured on the indicated days.
TIM-4-AMPKa1 Interaction
The interaction between TIM-4 and AMPKa1 in macrophages loaded with
chemotherapy-treated tumor cells was evaluated by immunoprecipitation
and immunofluorescence microscopy (see Supplemental Experimental
Procedures).
Statistics
The differences between two groups were determined by the Student’s t test
or the two-sample t test with Welch’s correction. The differences among three
ormore groupswere determined by a one-way ANOVA. p values less than 0.05
are considered statistically significant. * p < 0.05, ns: not significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.immuni.2013.09.014.
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